• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BeyondSpring Inc. (Amendment)

    2/11/22 3:01:00 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BYSI alert in real time by email
    SC 13G/A 1 brhc10033802_sc13ga.htm SC 13G/A

    United States
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*
     
    BeyondSpring Inc.
    (Name of Issuer)
     
    Ordinary Shares, par value $0.0001 per share
    (Title of Class of Securities)
     
    G10830100
    (CUSIP Number)
     
    December 31, 2021
    (Date of Event Which Requires Filing this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐
    Rule 13d-1(b)
    ☐
    Rule 13d-1(c)
    ☒
    Rule 13d-1(d)

    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. G10830100
    SCHEDULE 13G
    Page 2 of 12

    1
    NAMES OF REPORTING PERSONS
     
     
    Ever Regal Group Limited
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    British Virgin Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    3,660,000
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    3,660,000
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,660,000
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    9.35% (1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

     
    (1)
    Based on 39,142,253 Ordinary Shares of BeyondSpring Inc. (the “Ordinary Shares”) outstanding as of September 30, 2021.

    CUSIP No. G10830100
    SCHEDULE 13G
    Page 3 of 12

    1
    NAMES OF REPORTING PERSONS
     
     
    Fairy Eagle Investments Limited
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    British Virgin Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    4,620,000
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    4,620,000
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    4,620,000
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    11.80% (1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

     
    (1)
    Based on 39,142,253 Ordinary Shares outstanding as of September 30, 2021.

    CUSIP No. G10830100
    SCHEDULE 13G
    Page 4 of 12

    1
    NAMES OF REPORTING PERSONS
     
     
    Rosy Time Holdings Limited
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    British Virgin Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    1,190,000
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    1,190,000
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,190,000
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    3.04% (1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

     
    (1)
    Based on 39,142,253 Ordinary Shares outstanding as of September 30, 2021.

    CUSIP No. G10830100
    SCHEDULE 13G
    Page 5 of 12

    1
    NAMES OF REPORTING PERSONS
     
     
    Lan Huang
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    China
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    10,370,523(1)
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    10,370,523(1)
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    10,370,523(1)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    26.49% (2)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

     
    (1)
    Includes 4,620,000 Ordinary Shares owned directly by Fairy Eagle Investments Limited, 1,190,000 Ordinary Shares owned directly by Rosy Time Holdings Limited, 3,660,000 Ordinary Shares owned directly by Ever Regal Group Limited, 171,686 Ordinary Shares owned directly by the Lan Huang 2020 Grantor Retained Annuity Trust, 431,800 Ordinary Shares owned directly by Dr. Lan Huang and 137,037 Ordinary Shares owned directly by Mr. Linqing Jia. Also includes 160,000 Ordinary Shares owned directly by Dalian Wanchun Biotechnology Co., Ltd. (“Wanchun Biotech”). Dr. Lan Huang and Mr. Jia, her spouse, jointly own 100% of the equity interests in Wanchun Biotech. Dr. Huang and Mr. Jia share voting and dispositive power for all of the foregoing shares.

     
    (2)
    Based on 39,142,253 Ordinary Shares outstanding as of September 30, 2021.

    CUSIP No. G10830100
    SCHEDULE 13G
    Page 6 of 12

    1
    NAMES OF REPORTING PERSONS
     
     
    Linqing Jia
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    China
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    10,370,523(1)
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    10,370,523(1)
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    10,370,523(1)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    26.49% (2)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

     
    (1)
    Includes 4,620,000 Ordinary Shares owned directly by Fairy Eagle Investments Limited, 1,190,000 Ordinary Shares owned directly by Rosy Time Holdings Limited, 3,660,000 Ordinary Shares owned directly by Ever Regal Group Limited, 171,686 Ordinary Shares owned directly by the Lan Huang 2020 Grantor Retained Annuity Trust, 431,800 Ordinary Shares owned directly by Dr. Lan Huang and 137,037 Ordinary Shares owned directly by Mr. Jia. Also includes 160,000 Ordinary Shares owned directly by Wanchun Biotech. Mr. Jia and Dr. Huang, his spouse, jointly own 100% of the equity interests in Wanchun Biotech. Dr. Huang and Mr. Jia share voting and dispositive power for all of the foregoing shares.

     
    (2)
    Based on 39,142,253 Ordinary Shares outstanding as of September 30, 2021.

    CUSIP No. G10830100
    SCHEDULE 13G
    Page 7 of 12

    Item 1(a)
    Name of Issuer:
     
    BeyondSpring Inc. (the “Issuer”)
     
    Item 1(b)
    Address of Issuer’s Principal Executive Offices:
     
    28 Liberty Street, 39th Floor
    New York, New York 10005
     
    Item 2(a)-(c)
    Name of Persons Filing; Address of Principal Business Office; and Citizenship
     
    This Schedule 13G/A is filed jointly by each of the following persons (each a “Reporting Person” and, collectively, as the “Reporting Persons”) pursuant to a joint filing agreement entered into by the Reporting Persons in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, a copy of which was filed with the Schedule 13G filed by the Reporting Persons on February 14, 2018, as Exhibit 1 and is incorporated herein by reference:
     

    1.
    Ever Regal Group Limited, a limited liability company organized under the laws of the British Virgin Islands (“Ever Regal”), in its capacity as the direct owner of 3,660,000 of the Issuer’s Ordinary Shares, par value $0.0001 per share (“Ordinary Shares”);
     

    2.
    Fairy Eagle Investments Limited, a limited liability company organized under the laws of the British Virgin Islands (“Fairy Eagle”), in its capacity as the direct owner of 4,620,000 Ordinary Shares;
     

    3.
    Rosy Time Holdings Limited, a limited liability company organized under the laws of the British Virgin Islands (“Rosy Time”), in its capacity as the direct owner of 1,190,000 Ordinary Shares;
     

    4.
    Lan Huang, a Chinese citizen (“Dr. Huang”), in Dr. Huang’s capacity as the sole owner of Ever Regal; and
     

    5.
    Linqing Jia, a Chinese citizen (“Mr. Jia”), in Mr. Jia’s capacity as the sole owner of each of Fairy Eagle and Rosy Time.
     
    Dr. Huang is the Co-founder, Chairman and Chief Executive Officer of the Issuer. Mr. Jia is the Co-founder of the Issuer and the spouse of Dr. Huang. Dr. Huang is the sole trustee of the Lan Huang 2020 Grantor Retained Annuity Trust. Mr. Jia and Dr. Huang jointly own 100% of the equity interests in Wanchun Biotech.
     
    The principal business address for each of the Reporting Persons is c/o BeyondSpring Inc., 28 Liberty Street, 39th Floor, New York, NY 10005.
     
    Item 2(d)
    Title of class of securities:
     
    Ordinary Shares, par value $0.0001 per share
     
    Item 2(e)
    CUSIP Number:
     
    G10830100
     

    CUSIP No. G10830100
    SCHEDULE 13G
    Page 8 of 12

    Item 3.
    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a)
    ☐
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)
    ☐
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    ☐
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    ☐
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)
    ☐
    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f)
    ☐
    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g)
    ☐
    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h)
    ☐
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    ☐
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
    (j)
    ☐
    A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
    (k)
    ☐
    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

    If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:____________________________

    Item 4.
    Ownership:
     
    A.
    Ever Regal
       
     
    Amount beneficially owned: 3,660,000
       
       Percent of class: 9.35%
       
     
    Number of shares as to which the person has:
     
    (i) Sole Voting Power:
    0
     
    (ii) Shared Voting Power:
    3,660,000
     
    (iii) Sole Dispositive Power:
    0
     
    (iv) Shared Dispositive Power:
    3,660,000


    CUSIP No. G10830100
    SCHEDULE 13G
    Page 9 of 12

    B.
    Fairy Eagle
     
         
     
    Amount beneficially owned: 4,620,000
     
         
       Percent of class: 11.80%  
         
     
    Number of shares as to which the person has:
     
     
    (i) Sole Voting Power:
    0
     
    (ii) Shared Voting Power:
    4,620,000
     
    (iii) Sole Dispositive Power:
    0
     
    (iv) Shared Dispositive Power:
    4,620,000
         
    C.
    Rosy Time
     
         
     
    Amount beneficially owned: 1,190,000
     
         
     
    Percent of class: 3.04%
     
         
     
    Number of shares as to which the person has:
     
     
    (i) Sole Voting Power:
    0
     
    (ii) Shared Voting Power:
    1,190,000
     
    (iii) Sole Dispositive Power:
    0
     
    (iv) Shared Dispositive Power:
    1,190,000
         
    D.
    Dr. Huang
     
         
     
    Amount beneficially owned: 10,370,523
     
         
     
    Percent of class: 26.49%
     
         
     
    Number of shares as to which the person has:
     
     
    (i) Sole Voting Power:
    0
     
    (ii) Shared Voting Power:
    10,370,523
     
    (iii) Sole Dispositive Power:
    0
     
    (iv) Shared Dispositive Power:
    10,370,523
         
    E.
    Mr. Jia
     
         
     
    Amount beneficially owned: 10,370,523
     
         
     
    Percent of class: 26.49%
     
         
     
    Number of shares as to which the person has:
     
     
    (i) Sole Voting Power:
    0
     
    (ii) Shared Voting Power:
    10,370,523
     
    (iii) Sole Dispositive Power:
    0
     
    (iv) Shared Dispositive Power:
    10,370,523
     
    Dr. Huang is the sole owner of Ever Regal and, as such, has the ability to direct the management of the business of Ever Regal, including the power to direct decisions regarding the vote and disposition of securities held by Ever Regal; therefore, Dr. Huang may be deemed to have indirect beneficial ownership of the Ordinary Shares directly beneficially owned by Ever Regal. Dr. Huang is the spouse of Mr. Jia.

    CUSIP No. G10830100
    SCHEDULE 13G
    Page 10 of 12
     
    Mr. Jia is the sole owner of each of Fairy Eagle and Rosy Time and, as such, has the ability to direct the management of the business of each of Fairy Eagle and Rosy Time, including the power to direct decisions regarding the vote and disposition of securities held by each of Fairy Eagle and Rosy Time; therefore, Mr. Jia may be deemed to have indirect beneficial ownership of the Ordinary Shares directly beneficially owned by each of Fairy Eagle and Rosy Time. Mr. Jia is the spouse of Dr. Huang.
     
    The percentages used in this Schedule 13G/A are calculated based upon the Issuer’s 39,142,253 issued and outstanding Ordinary Shares as of September 30, 2021, as reported by the Issuer in its press release, attached as Exhibit 99.1 to its Form 6-K filed with the U.S. Securities and Exchange Commission on December 30, 2021.
     
    Pursuant to Rule 13d-4 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Reporting Persons declare that filing this Schedule 13G/A shall not be construed as an admission that any such person is, for the purposes of Section 13(d) and/or Section 13(g) of the Exchange Act, the beneficial owner of any securities covered by this Schedule 13G/A except to the extent of such person’s pecuniary interest in the Ordinary Shares, and, except to the extent of its, her or his pecuniary interest, such beneficial ownership is expressly disclaimed by each Reporting Person.
     
    Item 5.
    Ownership of 5 Percent or Less of a Class.
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐
     
    Item 6.
    Ownership of More than 5 Percent on Behalf of Another Person.
     
    Not applicable.
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not applicable.
     
    Item 8.
    Identification and Classification of Members of the Group.
     
    Not applicable.
     
    Item 9.
    Notice of Dissolution of Group.
     
    Not applicable.
     
    Item 10.
    Certifications.
     
    Not applicable.
     

    CUSIP No. G10830100
    SCHEDULE 13G
    Page 10 of 12
     
    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
    Date: February 7, 2022
     
           
     
    EVER REGAL GROUP LIMITED
     
           
     
    By:
    /s/ Lan Huang
     
     
    Name:
    Lan Huang
     
     
    Title:
    Director
     

     
    FAIRY EAGLE INVESTMENTS LIMITED
     
           
     
    By:
    /s/ Linqing Jia
     
     
    Name:
    Linqing Jia
     
     
    Title:
    Director
     

     
    ROSY TIME HOLDINGS LIMITED
     
           
     
    By:
    /s/ Linqing Jia
     
     
    Name:
    Linqing Jia
     
     
    Title:
    Director
     

     
    /s/ Lan Huang
     
     
    Lan Huang
     

     
    /s/ Linqing Jia
     
     
    Linqing Jia
     
     

    CUSIP No. G10830100
    SCHEDULE 13G
    Page 12 of 12

    EXHIBIT INDEX

    Exhibit  1
    Joint Filing Agreement, dated as of February 14, 2018, by and among Ever Regal Group Limited, Fairy Eagle Investments Limited, Rosy Time Holdings Limited, Lan Huang and Linqing Jia, as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (incorporated herein by reference to Exhibit 1 of the Schedule 13G filed by the Reporting Persons on February 14, 2018).

     

    Get the next $BYSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BYSI

    DatePrice TargetRatingAnalyst
    12/2/2021$38.00 → $5.00Buy → Hold
    Jefferies
    12/2/2021$45.00 → $5.00Buy → Underperform
    B of A Securities
    12/1/2021Outperform → Mkt Perform
    William Blair
    12/1/2021Buy → Neutral
    H.C. Wainwright
    9/20/2021$100.00 → $65.00Buy
    HC Wainwright & Co.
    9/9/2021$50.00Outperform
    Robert W. Baird
    9/9/2021$50.00Outperform
    Baird
    8/4/2021$100.00Neutral → Buy
    HC Wainwright & Co.
    More analyst ratings

    $BYSI
    Leadership Updates

    Live Leadership Updates

    See more
    • SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors

      NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (SEED), an innovative global biotech company focused on engineering "molecular glues" and harnessing its targeted protein degradation (TPD) platform to attack previously undruggable targets, has appointed eminent international lawyer Ko-Yung Tung to its Board of Directors. SEED is a subsidiary of BeyondSpring (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. Mr. Tung has served as a director and strategic advisor to leading international corporations and advisory councils, including Eisai Co., Ltd., Hawa

      10/23/23 7:45:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors

      Former Director at Eli Lilly, HSBC and MastercardBrings Almost Five Decades of Experience in Finance, Strategy and Risk Governance NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (the "Company"), a BeyondSpring (NASDAQ:BYSI) subsidiary and global research company focused on harnessing and engineering "molecular glues," a targeted protein degradation (TPD) platform to attack previously believed undruggable targets, today announced that it has appointed Jackson Tai to its Board of Directors. Mr. Tai has most recently retired, or will soon retire, as a Non-Executive Director of Eli Lilly (after 10 years), HSBC (after 7 years), and Mastercard (after 15 years). He brings almost 5

      6/20/23 8:00:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation

      SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the appointment of Richard John Daly ("Mr. Daly") as the President of CARsgen Therapeutics Corporation, a subsidiary of the Company in the United States. Mr. Daly will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Mr. Daly will lead the CARsgen U.S. team for the international business activities of CARsgen outside of China, including clinical development, CMC operation, busin

      1/17/22 8:50:00 AM ET
      $BYSI
      $CPRX
      $OPNT
      $PALI
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $BYSI
    Financials

    Live finance-specific insights

    See more
    • BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones

      Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. DocetaxelPlinabulin Phase 2 Data Highlights Potential to Resensitize Tumors Progressed on PD-1/PD-L1 Inhibitors in Metastatic NSCLCSEED Therapeutics Enters into Targeted Protein Degradation Research Collaboration with Eisai with potential payment to SEED of up to $1.5 Billion and Completes $24 Million First Close of Series A-3 FinancingSEED Therapeutics' Lead Oncology Asset RBM39 Degrader Granted Rare Pediatric Disease and Orphan Drug Designations by the FDA FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI

      3/27/25 7:00:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

      FLORHAM PARK, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the current unmet medical needs and the potential of Plinabulin as a novel immunochemotherapeutic in drug combinations and updates for SEED Therapeutics on Wednesday, May 15th, 2024 at 10:00 a.m. ET. The conference call and webinar will feature presentations by Key Opinion Leaders (KOLs) Trevor M. Feinstein, M.D. (Piedmont Cancer Institute), Alberto Chiappori, M.D. (Moffitt Cancer Center), an

      5/3/24 7:00:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors

      New Clinical Data from MD Anderson Presented at the Society for Immunotherapy of Cancer's 38th Annual Meeting80% DCR (disease control rate) in non-radiated tumor with Durable Responses in Heavily Pretreated Patients in 6 different cancersFull data was presented at SITC's 38th Annual Meeting; The Company will host a call at 8:30 a.m. ET today. Dial in: 877-407-0792, conference title: Clinical Significance of Plinabulin SITC Presentation with PI Dr. Steven Lin from MD Anderson NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platfor

      11/7/23 7:00:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BYSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Kirkby Matthew

      4 - BeyondSpring Inc. (0001677940) (Issuer)

      4/23/25 9:00:36 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Huang Lan

      4 - BeyondSpring Inc. (0001677940) (Issuer)

      4/23/25 9:00:05 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Delaney Brendan

      4 - BeyondSpring Inc. (0001677940) (Issuer)

      4/23/25 8:59:42 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BYSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting

      FLORHAM PARK, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster presentation on 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) and BeyondSpring in 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 30 through June 3 in Chicago, IL. ​​Presentation details are as follows: Title: Phase 2 Study of Pembrolizumab (Pembro) plus Plinabulin (Pli

      5/28/25 7:00:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

      Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD‑1/L1 therapySEED's first‑in‑class RBM39 degrader, reported at AACR 2025 for its total tumor regression data in mechanism targeted cancer indication-Ewing Sarcoma, remains on track for IND filing mid‑2025 FLORHAM PARK, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a clinical‑stage global biopharmaceutical company focused on developing cancer therapeutics, today announced its unaudited financial results for the quarter ended March 31, 2025, and provided a corporate update. "Plinabulin has now been administered to more than 7

      5/12/25 4:30:44 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring Files 2024 Annual Report on Form 10-K

      FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission ("SEC") on March 27, 2025. The annual report on Form 10-K, which contains the Company's audited consolidated financial statements, can be accessed on the SEC's website at www.sec.gov and on the Company's website at www.beyondspringpharma.com under "Financials & Filings" in the Investors section. The Company will provide

      3/27/25 7:05:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BYSI
    SEC Filings

    See more

    $BYSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $BYSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 10-Q filed by BeyondSpring Inc.

      10-Q - BeyondSpring Inc. (0001677940) (Filer)

      5/12/25 4:31:17 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BeyondSpring Inc. (0001677940) (Filer)

      5/12/25 4:30:15 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by BeyondSpring Inc.

      10-K - BeyondSpring Inc. (0001677940) (Filer)

      3/27/25 7:06:20 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BeyondSpring Inc.

      SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

      11/14/24 9:52:50 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by BeyondSpring Inc. (Amendment)

      SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

      2/14/24 4:30:59 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by BeyondSpring Inc. (Amendment)

      SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

      4/7/23 5:02:43 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring downgraded by Jefferies with a new price target

      Jefferies downgraded BeyondSpring from Buy to Hold and set a new price target of $5.00 from $38.00 previously

      12/2/21 5:17:19 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring downgraded by B of A Securities with a new price target

      B of A Securities downgraded BeyondSpring from Buy to Underperform and set a new price target of $5.00 from $45.00 previously

      12/2/21 4:49:29 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring downgraded by William Blair

      William Blair downgraded BeyondSpring from Outperform to Mkt Perform

      12/1/21 10:55:31 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care